Targeted inhibitors of EGFR: structure, biology, biomarkers, and clinical applications
N Shaban, D Kamashev, A Emelianova, A Buzdin - Cells, 2023 - mdpi.com
Members of the EGFR family of tyrosine kinase receptors are major regulators of cellular
proliferation, differentiation, and survival. In humans, abnormal activation of EGFR is …
proliferation, differentiation, and survival. In humans, abnormal activation of EGFR is …
Understanding resistance to EGFR inhibitors—impact on future treatment strategies
DL Wheeler, EF Dunn, PM Harari - Nature reviews Clinical oncology, 2010 - nature.com
EGFR is a tyrosine kinase that participates in the regulation of cellular homeostasis.
Following ligand binding, EGFR stimulates downstream cell signaling cascades that …
Following ligand binding, EGFR stimulates downstream cell signaling cascades that …
Mechanisms of resistance to EGFR targeted therapies
G Hrustanovic, BJ Lee, TG Bivona - Cancer biology & therapy, 2013 - Taylor & Francis
EGFR is a validated therapeutic target in many human cancers. EGFR targeted therapies
are in widespread clinical use in patients with non-small cell lung cancer and other tumor …
are in widespread clinical use in patients with non-small cell lung cancer and other tumor …
Heterogeneous mechanisms of primary and acquired resistance to third-generation EGFR inhibitors
S Ortiz-Cuaran, M Scheffler, D Plenker, L Dahmen… - Clinical Cancer …, 2016 - AACR
Purpose: To identify novel mechanisms of resistance to third-generation EGFR inhibitors in
patients with lung adenocarcinoma that progressed under therapy with either AZD9291 or …
patients with lung adenocarcinoma that progressed under therapy with either AZD9291 or …
Targeting the EGFR signaling pathway in cancer therapy
P Seshacharyulu, MP Ponnusamy… - Expert opinion on …, 2012 - Taylor & Francis
Introduction: Cancer is a devastating disease; however, several therapeutic advances have
recently been made, wherein EGFR and its family members have emerged as useful …
recently been made, wherein EGFR and its family members have emerged as useful …
Strategies to overcome acquired resistances conferred by mutations in the kinase domain of EGFR
Deregulation of EGFR is involved in the development of many cancers. The inhibition of
EGFR kinase activity has been clinically validated as a promising approach for the treatment …
EGFR kinase activity has been clinically validated as a promising approach for the treatment …
Rethink of EGFR in cancer with its kinase independent function on board
R Thomas, Z Weihua - Frontiers in oncology, 2019 - frontiersin.org
The epidermal growth factor receptor (EGFR) is one of most potent oncogenes that are
commonly altered in cancers. As a receptor tyrosine kinase, EGFR's kinase activity has been …
commonly altered in cancers. As a receptor tyrosine kinase, EGFR's kinase activity has been …
Mechanisms of tumor resistance to EGFR-targeted therapies
EA Hopper-Borge, RE Nasto, V Ratushny… - Expert opinion on …, 2009 - Taylor & Francis
Background: Much effort has been devoted to development of cancer therapies targeting
EGFR, based on its role in regulating cell growth. Small-molecule and antibody EGFR …
EGFR, based on its role in regulating cell growth. Small-molecule and antibody EGFR …
Mechanisms of resistance to EGFR inhibitors
R Bianco, T Gelardi, V Damiano, F Ciardiello… - Targeted Oncology, 2007 - Springer
The epidermal growth factor receptor (EGFR) autocrine pathway plays a crucial role in
human cancer, contributing to a number of highly relevant processes in tumor development …
human cancer, contributing to a number of highly relevant processes in tumor development …
A third shot at EGFR: new opportunities in cancer therapy
S Guardiola, M Varese, M Sanchez-Navarro… - Trends in …, 2019 - cell.com
Epidermal growth factor receptor (EGFR) inhibitors were among the first type of targeted
agents discovered in cancer and currently constitute the standard of care for a wide range of …
agents discovered in cancer and currently constitute the standard of care for a wide range of …